Primary liver cancer CNLC IIIa stage
Conditions
Interventions
Potential Response Team:NA
Potential unresponsive group:NA
Sponsors
Jiangjin District Central Hospital, Chongqing
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Model building 1 Preoperative MRI or CT enhanced scan of the upper abdomen, which conforms to the ‘fast in and fast out’ enhancement characteristics or liver biopsy for clear diagnosis; 2 Diagnosed with portal vein thrombosis by CTA or DSA, consistent with CNLC stage IIIa; 3 The results of the Child Pugh modified grading system for liver function are grade B or above, and the liver function reserve test (indocyanine green method) meets the requirements of interventional therapy and radiation therapy; 4 The HAIC combined with RT treatment plan has been completed and meets the follow-up requirements. Model validation 1. Preoperative MRI enhancement scan or CT enhancement scan of the upper abdomen, and in line with the enhancement characteristics of ‘fast in and fast out’ or liver biopsy to confirm the diagnosis; 2. Confirmed presence of portal vein cancer thrombosis by CTA or DSA, in line with CNLC stage IIIa; 3. Liver function Child-Pugh modified grading method assessment result B or above, and liver function reserve test (indocyanine green method) meets the requirements of interventional and radiotherapy; 4. No chemoradiotherapy and interventional therapy have been carried out since diagnosis.
Exclusion criteria
Exclusion criteria: Model building 1.Patients with extensive and multiple metastases of liver cancer; 2.Child Pugh C liver function, large amount of ascites, severe jaundice, and severe bleeding tendency;3. Poor overall condition or cachexia; 4. Merge malignant tumors of the gastrointestinal tract and other systems. Model validation 1. Patients with extensive multiple metastases of liver cancer; 2. Child-pugh C of liver function, massive ascites, severe jaundice, severe bleeding tendency; 3. Poor general condition or cachexia; 4. Malignant tumors combined with other systems such as the gastrointestinal tract; 5. Patients who refuse to sign the consent form for treatment to enroll or patients who are unable to tolerate the treatment regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate ; | — |
Countries
China
Contacts
Public ContactHaoyang Tan
Jiangjin District Central Hospital, Chongqing
Outcome results
None listed